patient; messages may not have been received. As the initial response to more regular follow up was positive, consideration should be made to whether a pre-arranged phone clinic would be more suitable. Future research could focus on reasons why CYP/their families are reluctant to engage, and ways to empower CYP to change.

To pave the way forward a patient questionnaire evaluating the current service and seeking opinions regarding regular, remote follow up would be valuable.

P18
EFFECTIVENESS OF HOME BOWEL PREPARATION FOR CHILDREN LIVING LONG DISTANCES FROM ENDOSCOPY CENTRE

Jamie Motion, Malcolm Sutherland, Brenda Smart, Carol Cameron, Shyla Kishore, Iain Chalmers, Su Burn. NHS Grampian

Introduction The North of Scotland Paediatric Gastroenterology, Hepatology and Nutrition Network (NoSPGHANN) manages children over an area of 53,000 km². Travel distances to Royal Aberdeen Children’s Hospital (RACH) were previously felt to preclude the adoption of home bowel preparation (HBP) for elective colonoscopies but a trial period of HBP commenced in March 2020. The same drugs (senna and Picolax) were used for inpatient bowel preparation (IPBP) or HBP but the timings were changed for HBP to complete all doses on the day prior to procedure to allow travel to RACH. This audit evaluates the impact of this change of practice.

Methods All children undergoing elective colonoscopy at RACH between December 2019 and November 2020 were identified. Electronic were records reviewed to determine IPBP vs HBP; distance to RACH from patient’s home, bowel preparation score, morning or afternoon list, requirement for intravenous (IV) fluids during the procedure, day case procedure and length of stay. Bowel preparation score was derived from the Aronchick Scale and converted as follows: 0 (unacceptable), 1 (poor), 2 (fair), 3 (good) and 4 (excellent).

Results Summary The high standard of bowel preparation achieved with IPBP was maintained when delivered at home, despite some children travelling >100 miles and having travelling times of >3 hours. Delivering all doses of drugs on the day prior to procedure did not affect the quality of bowel preparation for afternoon lists. There is a trend to a higher proportion of children with HBP receiving IV fluids during anaesthetic which may suggest that some are dehydrated. The proportion of day case procedures has increased from 0% to 72%, which since March 2020, has saved NHS Grampian £18,000.

Conclusion Home bowel preparation delivered on day prior to procedure is well tolerated and as effective as inpatient delivered, even for children with long travelling times to hospital. Covid-19 distancing measures have reduced the number of available inpatient beds so HBP has aided bed management in addition to providing a cost saving. The risk of dehydration may be higher for HBP and guidance will be changed to increase the emphasis on oral fluid intake, including during travelling time, on day of procedure.

P19
Efficacy of thiopurines in preventing infliximab antibody formation when used in dual therapy: experience from a single tertiary paediatric gastroenterology department

Muhamad Azim Muhamad Amin, Vansha Datta, Danica Hapuarachchi, Loveday Jago, Andrew Fagbemi, Ahmed Kadir. Royal Manchester Children Hospital, Manchester

Background and Aim There is evidence that shows addition of an immunomodulator (azathioprine or mercaptopurine) to Infliximab (IFX) therapy reduces antidrug antibodies, however, published evidence remains quite limited in paediatric population. We conducted a review to observe whether there is any correlation between the drug level of azathioprine metabolites, that is 6-thiouguanine nucleotides (6-TGN) and development of anti-IFX antibodies (Abs) in inflammatory bowel disease (IBD) patients.

Method This is a retrospective study of patients with IBD based on a single tertiary paediatric gastroenterology department that had their levels monitored from March 2016 until March 2020. We defined maximum drug efficacy based on consensus on ESPGHAN management of IBD in paediatric and our lab references (235–450 pmol/l × 108). In order to maintain consistencies, we included patients on 8 weekly 5 mg/kg of Infliximab infusion regimen who had their azathioprine metabolites measured within 3 months from starting. Fishers test and Pearson correlation were used to test the correlation between the drug level of azathioprine metabolites and development of IFX Abs.

Results 36 (58%) out of 62 patients were included in this study based on the above criteria (median age 14.25). Mean level of 6-TGN was lower in anti-IFX Abs-positive patients compared to anti-IFX Abs-negative patients (316.2 vs 322.8) with 6.607±57.51 (CI -123.5 to 110.3, p=0.91). There is a positive correlation between positive Anti-IFX Abs with lower level of Azathioprine metabolites with coefficient at 0.47 (p=0.05).

Conclusion Our data demonstrates there is positive correlation between lower levels of azathioprine metabolites and positive anti-IFX abs level, hence suggestive of the importance of adherence to treatment to ensure longevity usage infliximab in IBD patients.

P20
EMERGENCi: A UK PROSPECTIVE SURVEY OF SEVERE GI BLEEDING (REQUIRING UPPER GI ENDOSCOPY) AND EMERGENCY ENDOSCOPY IN UNDER 16S

1Natasha Thom, 1Martina Vallorani, 1Rамина Krupanathan, ①Polychronis Kemos, 2Nicholas Croft. 1Paediatric Gastroenterology, Royal London Children’s Hospital, Barts Health NHS Trust, London; ①Blizard Institute, Barts and the London School of Medicine, Queen Mary University of London

Background There is evidence that shows addition of an immunomodulator (azathioprine or mercaptopurine) to Infliximab (IFX) therapy reduces antidrug antibodies, however, published evidence remains quite limited in paediatric population. We conducted a review to observe whether there is any correlation between the drug level of azathioprine metabolites, that is 6-thiouguanine nucleotides (6-TGN) and development of anti-IFX antibodies (Abs) in inflammatory bowel disease (IBD) patients.

Method This is a retrospective study of patients with IBD based on a single tertiary paediatric gastroenterology department that had their levels monitored from March 2016 until March 2020. We defined maximum drug efficacy based on consensus on ESPGHAN management of IBD in paediatric and our lab references (235–450 pmol/l × 108). In order to maintain consistencies, we included patients on 8 weekly 5 mg/kg of Infliximab infusion regimen who had their azathioprine metabolites measured within 3 months from starting. Fishers test and Pearson correlation were used to test the correlation between the drug level of azathioprine metabolites, that is 6-thiouguanine nucleotides (6-TGN) and development of anti-IFX antibodies (Abs) in inflammatory bowel disease (IBD) patients.

Results 36 (58%) out of 62 patients were included in this study based on the above criteria (median age 14.25). Mean level of 6-TGN was lower in anti-IFX Abs-positive patients compared to anti-IFX Abs-negative patients (316.2 vs 322.8) with 6.607±57.51 (CI -123.5 to 110.3, p=0.91). There is a positive correlation between positive Anti-IFX Abs with lower level of Azathioprine metabolites with coefficient at 0.47 (p=0.05).

Conclusion Our data demonstrates there is positive correlation between lower levels of azathioprine metabolites and positive anti-IFX abs level, hence suggestive of the importance of adherence to treatment to ensure longevity usage infliximab in IBD patients.